tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Nuchev Reports Record Revenue Growth in Q4 FY25

Story Highlights
Nuchev Reports Record Revenue Growth in Q4 FY25

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

The latest update is out from Nuchev Pty Ltd ( (AU:NUC) ).

Nuchev Pty Ltd reported a record quarterly revenue of $6.3 million for Q4 FY25, marking a 167% increase from the previous corresponding period. The company’s expansion into the Vietnamese market and a new Sales Agency Agreement with Brauer Natural Medicines and H&S Brand Corporation have been pivotal in driving growth. Oli6® Nutritional sales, particularly in the ANZ and China CBEC markets, have shown significant increases, with the brand outperforming the overall infant formula market. The company aims to achieve breakeven through continued market expansion and strategic partnerships.

The most recent analyst rating on (AU:NUC) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Nuchev Pty Ltd stock, see the AU:NUC Stock Forecast page.

More about Nuchev Pty Ltd

Nuchev Pty Ltd operates in the nutritional products industry, primarily focusing on the production and sale of Oli6® Nutritional products. The company targets markets in Australia, New Zealand, China, and Vietnam, with a strong emphasis on the infant formula category.

Average Trading Volume: 32,796

Technical Sentiment Signal: Sell

Current Market Cap: A$22M

See more insights into NUC stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1